Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer
NCT ID: NCT02529579
Last Updated: 2015-08-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
187 participants
INTERVENTIONAL
2015-06-30
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer
NCT02929797
Decitabine Combined With Gemcitabine in First-line Treatment of AdvancedPancreatic Cancer
NCT02685228
Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
NCT02278458
Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer
NCT02017015
A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002
NCT01608711
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gemcitabine
Standard Gemcitabine Therapy
Gemcitabine
standard Gemcitabine therapy
cellular immunotherapy & Gemcitabine
iAPA-DC/CTL adoptive cellular immunotherapy combined Standard Gemcitabine Therapy
iAPA-DC/CTL adoptive cellular immunotherapy
twice DC cell infusion and CTL cell infusion for 6 times
Gemcitabine
standard Gemcitabine therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
iAPA-DC/CTL adoptive cellular immunotherapy
twice DC cell infusion and CTL cell infusion for 6 times
Gemcitabine
standard Gemcitabine therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Both gender, aged 18-70 year-old
3. Bone marrow functioned well
4. Renal function normal
5. Liver function normal
6. patients are voluntary, and willing to sign informed consent
7. expected lifetime was at least 3 months
Exclusion Criteria
2. Accompanied with primary malignant tumor other than pancreas
3. with autoimmune disease
4. using corticosteroid or other suppress immune hormone treatment
5. had transplant operation of vital organs
6. active hepatitis
7. HIV positive
8. dysfunction in blood coagulation
9. serious diseases in circulatory and respiratory systems
10. pregnancy or breast-feeding women
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ImmunoGene Biotechology Co.,Ltd
UNKNOWN
Changhai Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhaoshen Li
director of department of gastroenterology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhaoshen Ii, MD
Role: PRINCIPAL_INVESTIGATOR
Changhai Hosptial,Second Military medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Changhai Hospital, Second Military Medical University
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
cellular immunotherapy
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.